Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03846453 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes
A Phase 3 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 637
- Enrollment target
NCT03846453 is a Phase 3 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 637 participants.
The verdict
NCT03846453, a Phase 3 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 637 participants
- Enrollment target
Study Summary
The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL HL036 Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2019-03-10 |
| Est. Completion | 2019-11-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03846453
The ClinicalTrials.gov registry entry for NCT03846453 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 637 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HanAll BioPharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03846453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03846453 about?
NCT03846453 is a clinical study titled "A Study to Assess Efficacy and Safety of HL036 in Subjects With Dry Eyes". The objective of this study was to compare the safety and efficacy of 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
What is the current status of trial NCT03846453?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 637 participants. The study started on 2019-03-10. Estimated completion is 2019-11-22.
What interventions are being tested in trial NCT03846453?
The interventions under investigation include: Placebo (BIOLOGICAL), HL036 Ophthalmic Solution (BIOLOGICAL).
Who is sponsoring clinical trial NCT03846453?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.